Efficacy and pharmacokinetics of the combination of etravirine plus raltegravir as novel dual antiretroviral maintenance regimen in HIV-infected patients

Casado, José L.; Bañón, Sara; Rodríguez, Miguel Ángel Palomero; Moreno, Ana; Moreno, Santiago

doi:10.1016/j.antiviral.2014.11.006

Cited by 16 publications

(7 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a prospective study conducted in Barcelona, Spain, the criteria for efficacy was a viral load <50 copies/mL, achieved by 84% of 25 patients at 48 weeks [74]. This finding was corroborated by a prospective observational study in Madrid, Spain, in which 96% of 25 patients were still virologically suppressed 48 weeks after switching to ETR/RAL dual therapy [77]. At the University of Bologna, Italy, a prospective study with 38 patients used a tighter viral load criteria of <20 copies/mL, and 81.6% of patients achieved this outcome at 48 weeks [73].…”

Section: Etr/ralmentioning

confidence: 76%

“…All of the patients switching off of EFV regimens saw neuropsychiatric improvements [74]. In another prospective study, 25 virologically suppressed cARTs patients who switched to ETR/RAL dual therapy saw significant drops from baseline in total cholesterol (−17 mg/dL, p = 0.01) and triglycerides (−42 mg/dL, p = 0.01) at week 48 [77]. An observational study with 38 virologically suppressed cARTs patients switching to ETR/RAL reported significant declines at week 48 in the total cholesterol (−44.3 mg/dL), triglycerides (−81.2 mg/dL), and prevalence of tubular proteinuria (−30.2%).…”

Section: Etr and Ralmentioning

confidence: 97%

See 1 more Smart Citation

Non-Nucleoside Reverse Transcriptase Inhibitors Join Forces with Integrase Inhibitors to Combat HIV

Himmel¹,

Arnold

2020

Pharmaceuticals

View full text Add to dashboard Cite

In the treatment of acquired immune deficiency syndrome (AIDS), the diarylpyrimidine (DAPY) analogs etravirine (ETR) and rilpivirine (RPV) have been widely effective against human immunodeficiency virus (HIV) variants that are resistant to other non-nucleoside reverse transcriptase inhibitors (NNRTIs). With non-inferior or improved efficacy, better safety profiles, and lower doses or pill burdens than other NNRTIs in the clinic, combination therapies including either of these two drugs have led to higher adherence than other NNRTI-containing treatments. In a separate development, HIV integrase strand transfer inhibitors (INSTIs) have shown efficacy in treating AIDS, including raltegravir (RAL), elvitegravir (EVG), cabotegravir (CAB), bictegravir (BIC), and dolutegravir (DTG). Of these, DTG and BIC perform better against a wide range of resistance mutations than other INSTIs. Nevertheless, drug-resistant combinations of mutations have begun to emerge against all DAPYs and INSTIs, attributable in part to non-adherence. New dual therapies that may promote better adherence combine ETR or RPV with an INSTI and have been safer and non-inferior to more traditional triple-drug treatments. Long-acting dual- and triple-therapies combining ETR or RPV with INSTIs are under study and may further improve adherence. Here, highly resistant emergent mutations and efficacy data on these novel treatments are reviewed. Overall, ETR or RPV, in combination with INSTIs, may be treatments of choice as long-term maintenance therapies that optimize efficacy, adherence, and safety.

show abstract

Section: Etr/ralmentioning

confidence: 76%

Section: Etr and Ralmentioning

confidence: 97%

Non-Nucleoside Reverse Transcriptase Inhibitors Join Forces with Integrase Inhibitors to Combat HIV

Himmel¹,

Arnold

2020

Pharmaceuticals

View full text Add to dashboard Cite

show abstract

“…First, we included only those patients who received RAL plus two nucleoside analogues, but in some cases the nucleoside backbone might be less effective due to previous failure and resistance. In such cases, and despite the lack of clinical trials, the combination of RAL with NNRTIs, including those that are not (rilpivirine) or are weak inducers of CYP450 isoenzimes (etravirine), could be an option [20,21]. Second, relapse or progression-free survival was not considered as secondary end points because the objectives of the study were to determine the efficacy and safety of RALbased cART.…”

Section: Discussionmentioning

confidence: 99%

Raltegravir plus Two Nucleoside Analogues as Combination Antiretroviral Therapy in HIV-Infected Patients who Require Cancer Chemotherapy

Casado¹,

Machuca²,

Bañón³

et al. 2014

Antiviral Therapy

Self Cite

View full text Add to dashboard Cite

show abstract

“…In the past, etravirine (ETR) plus raltegravir (RAL) were an alternative NRTI sparing option, even if burdened by a daily 4 pills regimen. 5,6…”

Section: Manuscriptmentioning

confidence: 99%

Maintenance of Viral Suppression after Optimization Therapy from Etravirine Plus Raltegravir to Rilpivirine Plus Dolutegravir in HIV-1-Infected Patients

Riccardi

Puente

Taramasso

et al. 2019

J Int Assoc Provid AIDS Care

View full text Add to dashboard Cite

Non-nucleoside reverse-transcriptase inhibitor plus integrase strand transfer inhibitor–based dual therapies are an attractive simplification, nucleoside reverse transcriptase inhibitor-sparing strategy for experienced human immunodeficiency virus-infected patients. Thus, we performed a 24-week real-life observational study to assess efficacy and safety of switching from raltegravir plus etravirine to dolutegravir plus rilpivirine in 7 previously heavily treated patients. This simplification strategy reduced pill burden and preserved viral suppression in treatment-experienced patients with no major mutations to rilpivirine at historical genotyping.

show abstract

Efficacy and pharmacokinetics of the combination of etravirine plus raltegravir as novel dual antiretroviral maintenance regimen in HIV-infected patients

Cited by 16 publications

References 15 publications

Non-Nucleoside Reverse Transcriptase Inhibitors Join Forces with Integrase Inhibitors to Combat HIV

Non-Nucleoside Reverse Transcriptase Inhibitors Join Forces with Integrase Inhibitors to Combat HIV

Raltegravir plus Two Nucleoside Analogues as Combination Antiretroviral Therapy in HIV-Infected Patients who Require Cancer Chemotherapy

Maintenance of Viral Suppression after Optimization Therapy from Etravirine Plus Raltegravir to Rilpivirine Plus Dolutegravir in HIV-1-Infected Patients

Contact Info

Product

Resources

About